New single-cell protocols available for full-length, whole transcriptome sequencing using microfluidics technology
Fluidigm Corporation today announced two new total RNA sequencing applications for the C1™ system. Available on Script Hub™, these single-cell workflows provide basic and translational researchers with powerful new tools to deeply characterize unique cellular subtypes and functional states.
Single-cell genomics is transforming our understanding of cellular diversity. Although initial advances have relied primarily on the measurement of protein-coding messenger RNAs (mRNAs), it is well-known that non-coding RNAs (ncRNAs) are also instrumental in regulating cell function and represent an exciting and growing class of diverse molecules that can control gene expression at both the transcriptional and post-transcriptional levels.
Using microfluidics technology, Fluidigm developed the C1 Total RNA Seq application to enable simultaneous detection of mRNAs and ncRNAs at single-cell resolution. Offered in conjunction with a bioinformatics pipeline, this full-length RNA sequencing application enables researchers to deeply characterize newly identified cell subpopulations in a more comprehensive and cost-effective manner than profiling mRNA alone.
“The C1 Total RNA Seq workflow will enable deep characterization of single cells downstream of cell atlasing studies, providing more biological information about each individual cell than with ultrahigh-throughput end counting methods,” said Dr. Sarah Teichmann, Head of Cellular Genetics at the Wellcome Sanger Institute.
Providing a second and complementary method for single-cell total RNA sequencing on the C1, the random displacement amplification sequencing (RamDA-seq) application offers a comprehensive view of total RNA. It enables researchers to study RNA processing events and transcriptional regulation at single-cell resolution by enabling highly sensitive detection of full-length mRNAs and non-poly(A) transcripts. Developed by Dr. Tetsutaro Hayashi and Dr. Itoshi Nikaido of the Riken Center for Biosystems Dynamics Research, the RamDA-seq method was published this year in the journal Nature Communications.
“RamDA-seq enables an understanding of single-cell localities such as non-poly(A) RNAs, pre-mRNAs and enhancer RNAs,” said Hayashi. “This will be invaluable to researchers working with rare cells in cancer biology, neurobiology and immune biology.”
“We are excited to bring comprehensive total RNA sequencing to single-cell research,” said Chris Linthwaite, President and CEO of Fluidigm. “We look forward to powering new insights in our understanding of health and disease.”
Source – Fluidigm